P51 e-DAM: An e-Delphi consensus survey to inform the clinical utility of AMBLorTM: a novel prognostic biomarker for American Joint Committee on Cancer stage I and II cutaneous malignant melanoma

Clicks: 3
ID: 318377
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #234 of 313 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and aims Cutaneous malignant melanoma (cMM) incidence continues to rise in the UK, creating unprecedented pressures on skin cancer services. Current American Joint Committee on Cancer (AJCC) staging provides only broad prognostic estimates, potentially leading to overtreatment in early-stage disease. AMBLor is a validated immunohistochemistry (IHC)-based biomarker that identifies nonulcerated AJCC stage I/II cMM at lower risk of progression. This study aimed to establish expert consensus on the potential clinical utility of AMBLor in personalizing early-stage cMM management. Methods A four-round modified e-Delphi survey was conducted between February 2023 and May 2025. Twenty-five UK skin specialist MDT (SSMDT) consultants participated in Round 1, with 18 completing all rounds. Rounds 1–2 explored challenges in managing early-stage cMM and potential biomarker use cases. Rounds 3–4 assessed the impact of an AMBLor low-risk result on key management scenarios identified from rounds 1–2, including sentinel lymph node biopsy (SLNB), adjuvant therapy, imaging and follow-up. Consensus was defined as strong (≥ 75%) or moderate (50–74%) agreement. Results Strong consensus emerged for biomarker utility in targeting radiological surveillance to higher-risk patients (100%), reducing follow-up for lower-risk patients (100%), prioritizing adjuvant therapy for highest-risk cases (95%), and improving SLNB selection (91%). In the context of an AMBLor low-risk result, moderate consensus supported not offering SLNB for pT1b melanoma (66%), adjuvant therapy for AJCC stage IIB melanoma (72%), computed tomography surveillance for stage IIB melanoma (50%) and reducing intensity of clinical surveillance for AJCC stages IA–IIA (50–56%). Conclusions The e-DAM study demonstrates strong expert support for integrating AMBLor into early-stage cMM clinical pathways. AMBLor-guided strategies could refine SLNB selection, rationalize adjuvant therapy and imaging provision, and reduce clinical follow-up burdens, thereby enhancing personalized care for patients with cMM, while alleviating service pressures. Prospective studies are now warranted to evaluate the real-world impact on outcomes, resource utilization, and patient experience.
Reference Key
openalex_W7165632867 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Krishna Ravulapalli, Diarmuid Coughlan, Rachel Abbott, Howard Peach, Michaela Fay, Penny Lovat, Aidan Rose
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag151.089
URL
https://doi.org/10.1093/bjd/ljag151.089
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.